Next-Generation Genomic Sequencing: Market Evaluation

A Panel Discussion Among Genomic Sequencing Experts

September 2007

Deliverable: Transcript with key findings

Study Description and Objectives

To assess potential future uptake of the Illumina 1G Genome Analyzer (using Solexa sequencing technology) and the competitive environment developing in the �next-generation sequencing� space

�    From current Illumina/Solexa users, determine:

�     Drivers of initial adoption

�     Current utilization and applications

�     Levels of satisfaction with the product/technology

�     Strengths and weaknesses of the product

�     Appetite for additional purchases

�    From those (e.g., core labs and smaller academic centers) evaluating the Illumina/Solexa product and others, determine:

�     Existing platforms now in use

�     Barriers to adoption

�     Specific competing products under consideration

�     Purchasing criteria

�     Purchasing timelines

�    From all participants, explore the attributes, merits, and demerits of competing products, including:

�     Applied Biosystems SOLiD system (now in market via �early access program�)

�     454 Life Sciences sequencer (marketed by Roche Diagnostics)

�     Helicos Biosciences tSMS platform

�    Explore specific additional issues, including:

�     Thoughts on the potential for de novo sequencing using Illumina/Solexa, others

�     Time horizon for single-molecule sequencing, and who will get there first

�     Potential for longer read lengths being accommodated by any of the competitors

�     The future of capillary sequencing

�     Other competing technologies not previously discussed

Companies and Products Mentioned in This Report

Inclusion Criteria and Panelist Demographics

Represented Institutions

To purchase this report or request additional information, contact: